$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

$lsta Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000032001714000007 Filed on March 13, 2014

Income Statement

Concept	2014 Q1	2013	2012 Q4
Revenue	$4.056K	$14.67M	$2.750M
YoY Change	60.7%	2.36%	-34.68%
Cost Of Revenue	$3.825M	$12.95M	$2.550M
YoY Change	59.92%	8.35%	-22.96%
Gross Profit	-$3.821M	$1.721M	$200.0K
YoY Change	-2998.88%	-27.7%	-77.78%
Gross Profit Margin	-94215.68%	11.73%	7.27%
Selling, General & Admin	$8.970M	$21.61M	$5.180M
YoY Change	54.61%	-3.15%	-18.94%
% of Gross Profit		1255.65%	2590.0%
Research & Development	$4.759M	$16.92M	$2.950M
YoY Change	50.54%	61.87%	43.2%
% of Gross Profit		982.86%	1475.0%
Depreciation & Amortization	$440.0K	$1.000M	$390.0K
YoY Change	-20.0%	0.0%	77.27%
% of Gross Profit		58.1%	195.0%
Operating Expenses	$17.55M	$51.48M	$8.140M
YoY Change	54.59%	15.12%	-3.78%
Operating Profit	-$13.50M	-$36.81M	-$7.940M
YoY Change	52.85%	21.14%	5.03%
Interest Expense	$94.16K	$281.4K	-$220.0K
YoY Change	116.15%	-82.15%	-62.71%
% of Operating Profit
Other Income/Expense, Net	-$283.7K	-$1.896M	-$4.350M
YoY Change	760.92%	-67.81%	-952.94%
Pretax Income	-$13.78M	-$38.71M	-$12.51M
YoY Change	55.48%	6.69%	63.96%
Income Tax	$47.41K	$780.1K	-$180.0K
% Of Pretax Income
Net Earnings	-$13.68K	-$38.98M	-$15.51M
YoY Change	55.46%	-27.5%	-17.72%
Net Earnings / Revenue	-337.33%	-265.75%	-564.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$4.868M	-$19.01M	-$9.755M
COMMON SHARES
Basic Shares Outstanding	28.58M shares		159.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013	2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$41.40M	$46.10M	$13.70M
YoY Change	345.16%	236.5%	251.28%
Cash & Equivalents	$41.36M	$46.10M	$12.30M
Short-Term Investments
Other Short-Term Assets	$3.300M	$2.900M	$1.900M
YoY Change	32.0%	52.63%	-94.24%
Inventory	$1.476M		$1.113M
Prepaid Expenses
Receivables	$1.888M	$1.900M	$1.054M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$46.56M	$50.80M	$16.71M
YoY Change	267.26%	204.19%	-56.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.79M	$12.80M	$11.15M
YoY Change	27.76%	14.29%	-3.99%
Goodwill	$11.12M		$11.12M
YoY Change	0.0%		0.0%
Intangibles	$13.72M		$14.48M
YoY Change	-4.22%		-4.01%
Long-Term Investments
YoY Change
Other Assets	$1.205M	$1.200M	$947.3K
YoY Change	23.05%	33.33%	-71.53%
Total Long-Term Assets	$39.84M	$39.00M	$37.70M
YoY Change	7.03%	3.45%	-67.7%
TOTAL ASSETS
Total Short-Term Assets	$46.56M	$50.80M	$16.71M
Total Long-Term Assets	$39.84M	$39.00M	$37.70M
Total Assets	$86.39M	$89.80M	$54.41M
YoY Change	73.14%	65.07%	-64.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.296M	$3.400M	$2.555M
YoY Change	50.41%	30.77%	11.72%
Accrued Expenses	$2.382M	$4.000M	$2.285M
YoY Change	41.51%	73.91%	109.58%
Deferred Revenue
YoY Change
Short-Term Debt	$200.0K	$200.0K	$3.400M
YoY Change	-94.12%	-94.12%	-5.56%
Long-Term Debt Due	$800.0K	$400.0K	$200.0K
YoY Change	700.0%	100.0%	100.0%
Total Short-Term Liabilities	$8.786M	$9.800M	$9.949M
YoY Change	-4.79%	-1.01%	-72.7%
LONG-TERM LIABILITIES
Long-Term Debt	$3.800M	$3.600M	$200.0K
YoY Change	3700.0%	1700.0%	-95.83%
Other Long-Term Liabilities	$635.0K	$10.00M	$214.9K
YoY Change	130.62%	26.58%
Total Long-Term Liabilities	$27.33M	$13.60M	$21.59M
YoY Change	134.27%	67.9%	-36.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.786M	$9.800M	$9.949M
Total Long-Term Liabilities	$27.33M	$13.60M	$21.59M
Total Liabilities	$36.11M	$27.30M	$31.54M
YoY Change	72.85%	28.77%	-55.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$250.1M		-$197.4M
YoY Change	21.27%		37.95%
Common Stock	$28.59K		$16.38K
YoY Change	-83.21%		-85.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$705.7K		$665.6K
YoY Change	6.03%
Treasury Stock Shares			104.0K shares
Shareholders Equity	$59.64M	$62.50M	$33.18M
YoY Change
Total Liabilities & Shareholders Equity	$86.39M	$89.80M	$54.41M
YoY Change	73.14%	65.07%	-64.97%

Cashflow Statement

Concept	2014 Q1	2013	2012 Q4
OPERATING ACTIVITIES
Net Income	-$13.68K	-$38.98M	-$15.51M
YoY Change	55.46%	-27.5%	-17.72%
Depreciation, Depletion And Amortization	$440.0K	$1.000M	$390.0K
YoY Change	-20.0%	0.0%	77.27%
Cash From Operating Activities	-$11.25M	-$27.10M	-$9.620M
YoY Change	57.71%	95.64%	182.11%
INVESTING ACTIVITIES
Capital Expenditures	$1.240M	$2.691M	-$330.0K
YoY Change	2213.95%	406.57%	450.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$9.110M
YoY Change		-100.0%	699.12%
Cash From Investing Activities	-$1.240M	-$2.691M	$8.780M
YoY Change	2213.95%	-144.21%	712.96%
FINANCING ACTIVITIES
Cash Dividend Paid		$0.00
YoY Change		-100.0%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$7.719M	$62.19M	-1.680M
YoY Change	185.32%	611.41%	-147.32%
NET CHANGE
Cash From Operating Activities	-$11.25M	-$27.10M	-9.620M
Cash From Investing Activities	-$1.240M	-$2.691M	8.780M
Cash From Financing Activities	$7.719M	$62.19M	-1.680M
Net Change In Cash	-$4.774M	$32.40M	-2.520M
YoY Change	6.47%	3213.76%	-306.56%
FREE CASH FLOW
Cash From Operating Activities	-$11.25M	-$27.10M	-$9.620M
Capital Expenditures	$1.240M	$2.691M	-$330.0K
Free Cash Flow	-$12.49M	-$29.79M	-$9.290M
YoY Change	73.77%	107.13%	177.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	626054	USD
CY2013	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3354908	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2555240	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1053604	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1860835	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4018026	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2284813	USD
CY2013Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	4018.0	USD
CY2012Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2284.8	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	544.8	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	606.6	USD
CY2012Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	0.0	USD
CY2013Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	500.0	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2022500	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3022800	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	299594525	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	231218615	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6838700	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	391829	USD
CY2012	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1609495	USD
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	605200	USD
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	605200	USD
CY2012Q4	us-gaap	Assets Assets	54406263	USD
CY2013Q4	us-gaap	Assets Assets	89816082	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	50826750	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	16707216	USD
CY2012Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	23800300	USD
CY2013Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	11229900	USD
CY2012Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	99500	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13737452	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46133759	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	13737452	USD
CY2012Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	9897800	USD
CY2012Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value Noncurrent BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent	7550000	USD
CY2013Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value Noncurrent BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent	9450000	USD
CY2012	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability	-4420000	USD
CY2013	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability	-1900000	USD
CY2013Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	203100	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	46133759	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	12745432	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	992020	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	32396307	USD
CY2013Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	700000	USD
CY2012Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	800000	USD
CY2013	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0	USD
CY2012	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-8370228	USD
CY2012	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-5660305	USD
CY2013	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
CY2013	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
CY2012	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	4907407	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27196537	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16375365	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16375365	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27196537	shares
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	780.1	USD
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	476.9	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	16375	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	27197	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52057723	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38981244	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-12448950	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-504090	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-70521654	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-39485334	USD
CY2013Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
CY2012Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
CY2013	us-gaap	Cost Of Revenue CostOfRevenue	12947217	USD
CY2012	us-gaap	Cost Of Revenue CostOfRevenue	11949124	USD
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0.0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	13600	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	239700	USD
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	780104	USD
CY2013Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4444000	USD
CY2012Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3599100	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1816601	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1468341	USD
CY2012Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	6644500	USD
CY2013Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	7036800	USD
CY2012Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	391800	USD
CY2013Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	414900	USD
CY2013Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	10500	USD
CY2012Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	23100	USD
CY2012Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	287300	USD
CY2013Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	704600	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	35545600	USD
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-175.5	USD
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	303.2	USD
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-175.5	USD
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-175533	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	55347400	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	39144700	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	59791400	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25727700	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	43334800	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	348700	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7971900	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5466700	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	15200	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	304300	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20581700	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18441900	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3599100	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4379200	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	4379200	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	3599100	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	4379226	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3599122	USD
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1550571	USD
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1605608	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1000000	USD
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1000000	USD
CY2013Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	23175	USD
CY2012Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2013Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2012Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	101156	USD
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.00
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.90
CY2013	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2012	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	14389	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2012Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1597.2	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	2325.8	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1288200	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1893400	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	10849600	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	605200	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	605200	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	605200	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	605200	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	605200	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15769000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15769000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13875600	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14480800	USD
CY2012Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	683700	USD
CY2013Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	958000	USD
CY2013	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2012	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-13653	USD
CY2013Q4	us-gaap	Goodwill Goodwill	11117770	USD
CY2012Q4	us-gaap	Goodwill Goodwill	11117770	USD
CY2012	us-gaap	Gross Profit GrossProfit	2380765	USD
CY2013	us-gaap	Gross Profit GrossProfit	1721238	USD
CY2013	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-38981244	USD
CY2012	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-35814140	USD
CY2012	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-287181	USD
CY2013	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-504090	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-1094800	USD
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-12334100	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38705230	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-36276854	USD
CY2013	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-39485334	USD
CY2012	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-36101321	USD
CY2013	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.90
CY2012	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-2.59
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-30267990	USD
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-12312646	USD
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-17955344	USD
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.00
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-1.30
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-175533	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	780104	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	525700	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-13159800	USD
CY2012	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-384800	USD
CY2013	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-3822900	USD
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3430900	USD
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2154100	USD
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	2100000	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	573005	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	554884	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	178008	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	348260	USD
CY2013	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	36000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	157198	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	465280	USD
CY2012	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2414842	USD
CY2013	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	204422	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	178011	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	758798	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	13875617	USD
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14480827	USD
CY2013	us-gaap	Interest Expense InterestExpense	281421	USD
CY2012	us-gaap	Interest Expense InterestExpense	1576975	USD
CY2013	us-gaap	Interest Paid InterestPaid	274100	USD
CY2012	us-gaap	Interest Paid InterestPaid	1771800	USD
CY2012	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	182000	USD
CY2013	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	0	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	1113025	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	1270223	USD
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	6838559	USD
CY2012	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	6712536	USD
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1500000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1100000	USD
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	654500	USD
CY2013Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	674100	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89816082	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54406263	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9949427	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9806919	USD
CY2012Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	21586104	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	27789647	USD
CY2013Q4	us-gaap	Long Term Debt LongTermDebt	3023609	USD
CY2012Q4	us-gaap	Long Term Debt LongTermDebt	0	USD
CY2013Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	531164	USD
CY2012Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	171528	USD
CY2012Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	39500	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1151729	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1004000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	5900	USD
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	110600000	USD
CY2012Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	77100000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	81.0	USD
CY2013Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	58200	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	647.4	USD
CY2013Q4	us-gaap	Minority Interest MinorityInterest	-516040	USD
CY2012Q4	us-gaap	Minority Interest MinorityInterest	-356970	USD
CY2013	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">The Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">    </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. We are pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that cell therapy will play a large role in changing the natural history of diseases as more breakthrough therapies are developed, ultimately lessening the overall burden of disease on patients and their families as well as the economic burden that these diseases impose upon modern society.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business includes the development of novel proprietary cell therapy products as well as a revenue generating contract development and manufacturing service business that we not only leverage for the development of our therapeutics but anticipate will benefit from the advancement in the regenerative medicine industry. The combination of our own therapeutic development business and a revenue-generating service provider business provides the Company with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> We are developing therapies to address ischemia through our CD34 Cell Program. Ischemia occurs when the supply of oxygenated blood in the body is restricted. We seek to reverse this restriction through the development and formation of new blood vessels. AMR-001 is our most clinically advanced product candidate in our CD34 Cell Program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack) ("AMI"). In December 2013, the Company completed enrollment in its PreSERVE AMI study. PreSERVE AMI is a randomized, double-blinded, placebo-controlled Phase 2 clinical trial testing AMR-001, an autologous (donor and recipient are the same) adult stem cell product for the treatment of patients with left ventricular dysfunction following acute ST segment elevation myocardial infarction (STEMI). With infusion of the target population of 160 patients complete, the last patient primary endpoint follow-up for this study is expected in June 2014 followed by data lock and analysis with a submission for a possible presentation of the study at the American Heart Association's Scientific Sessions to be held November 15-19, 2014. If approved by Food and Drug Administration (the "FDA ") and/or other worldwide regulatory agencies following successful completion of further trials, AMR-001 would address a significant medical need for which there is currently no effective treatment, potentially improving longevity and quality of life for those suffering a STEMI, and positioning the Company to capture a meaningful share of this worldwide market. We also expect to initiate a Phase 2 clinical trial for chronic heart failure in Europe in 2014 and are conducting preclinical studies in traumatic brain injury for which we expect data in the second half of 2014.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Another platform technology we are developing utilizes T Regulatory Cells ("Tregs") to treat diseases caused by imbalances in the immune system. In collaborating with Becton-Dickinson and the University of California, San Francisco, we are utilizing this technology platform of our majority-owned subsidiary, Athelos Corporation ("Athelos"), to restore immune balance by enhancing Treg cell number and function. Tregs are a natural part of the human immune system and regulate the activity of T effector cells, the cells that are responsible for protecting the body from viruses and other foreign antigen exposure. When Tregs function properly, only foreign materials are attacked by T effector cells. In autoimmune disease it is thought that deficient Treg activity permits the T effector cells to attack the body's own tissues. We plan to initiate a Phase 2 study of Treg based therapeutics to treat type 1 diabetes in 2014. We also plan to initiate a Phase 1 study in Canada of Treg based therapeutics in support of a steroid resistant asthma indication in 2014.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-clinical assets include our VSEL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> TM</sup></font><font style="font-family:inherit;font-size:10pt;"> (Very Small Embryonic Like) Technology regenerative medicine platform. Regenerative medicine holds the promise of improving clinical outcomes and reducing overall  healthcare costs.  We are working on a Department of Defense funded study of VSELs</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;"> for the treatment of chronic wounds. Other preclinical work with VSELs</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM </sup></font><font style="font-family:inherit;font-size:10pt;">includes exploring macular degeneration as a target indication.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Progenitor Cell Therapy, LLC ("PCT") is a contract manufacturer that generates revenue. This wholly owned subsidiary, which we acquired in 2011, is an industry leader in providing high quality manufacturing capabilities and support to developers of cell-based therapies to enable them to improve efficiencies and profitability and reduce capital investment for their own development activities. Since its inception more than 15 years ago, PCT has provided pre-clinical and clinical current Good Manufacturing Practice (“cGMP”) development and manufacturing services to more than 100 clients. PCT has experience advancing regenerative medicine product candidates from product inception through rigorous quality standards all the way through to human testing, Biologic License Application ("BLA") filing and FDA product approval. PCT's core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, engineering and innovation services, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. The Company is pursuing commercial expansion of our manufacturing operations both in the U.S. and internationally. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective March 31, 2012, we no longer operated in the former Regenerative Medicine – China segment, which is now reported in discontinued operations (see Note 15). On November 13, 2012, we completed the sale of our 51% interest in Suzhou Erye, which represented the operations in our former Pharmaceutical Manufacturing - China segment, and is also reported in discontinued operations (see Note 15). As a result, we currently operate in a single reporting segment - Cell Therapy, which will focus on contract development and manufacturing and cell therapy development programs. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that NeoStem is ideally positioned to lead the cell therapy industry.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) and include the accounts of the Company and its wholly owned and partially owned subsidiaries, the operations of our former Regenerative Medicine - China segment through the deconsolidation date on March 31, 2012 (see Note 15), and the operations of our former Pharmaceutical Manufacturing - China segment through November 13, 2012, the date on which the segment was sold (see Note 15). These former segments are reported in discontinued operations. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, include all normal and recurring adjustments considered necessary to present fairly the Company's financial position as of December 31, </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2012</font><font style="font-family:inherit;font-size:10pt;">, and the results of its operations and its cash flows for the years then ended. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Examples of estimates include the fair value of goodwill and/or potential goodwill impairments for our reporting units, useful lives of our tangible and intangible assets, allowances for doubtful accounts, and stock-based compensation forfeiture rates. An example of an assumption includes the potential outcome of future tax consequences of events that have been recognized in our financial statements or tax returns. Accordingly, actual results could differ from those estimates and assumptions.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to the Consolidated Financial Statements and Notes to the Consolidated Financial Statements for the year ended December 31, 2012 to conform to the presentation for the year ended December 31, 2013. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Consolidated Financial Statements include the accounts of NeoStem, Inc. and its wholly owned and partially owned subsidiaries and affiliates as listed below, as well as the operations of our former Regenerative Medicine - China segment through the deconsolidation date on March 31, 2012 (see Note 15), and the operations of our former Pharmaceutical Manufacturing - China segment through November 13, 2012, representing the date which the segment was sold (see Note 15). These former segments are reported in discontinued operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="32%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="25%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Entity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percentage of Ownership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Location</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Parent  Company</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem Therapies, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stem Cell Technologies, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amorcyte, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Progenitor Cell Therapy, LLC (PCT)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem Family Storage, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Athelos Corporation (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PCT Allendale, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1) Pursuant to the Stock Purchase Agreement signed in March 2011, our initial ownership in Athelos was 80.1%, and Becton Dickinson's ("BD") initial minority ownership was 19.9%. Per the Agreement, BD will be diluted based on new investment in Athelos by us (subject to certain anti-dilution provisions). As of </font><font style="font-family:inherit;font-size:9pt;">December 31, 2013</font><font style="font-family:inherit;font-size:9pt;">, BD's ownership interest in Athelos was decreased to 11.5%, and our ownership increased to 88.5%. As a result in the change in ownership, approximately </font><font style="font-family:inherit;font-size:9pt;">$0.3 million</font><font style="font-family:inherit;font-size:9pt;"> was transferred from additional paid in capital to non-controlling interests.</font></div></div>
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	62189471	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8741769	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	62189471	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	17111997	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2691471	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6088380	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2691471	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	11748685	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13852518	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27101693	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18759925	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-27101693	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-53769484	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-38981244	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-38981244	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-55310326	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1896279	USD
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5891203	USD
CY2013Q4	us-gaap	Notes Payable NotesPayable	900000	USD
CY2012Q4	us-gaap	Notes Payable NotesPayable	400000	USD
CY2013Q4	us-gaap	Notes Payable Current NotesPayableCurrent	381097	USD
CY2012Q4	us-gaap	Notes Payable Current NotesPayableCurrent	202558	USD
CY2012Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2012Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2012	us-gaap	Operating Expenses OperatingExpenses	32766416	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	38530189	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-36808951	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-30385651	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2895000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	383400	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	671800	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	829900	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	947307	USD
CY2012	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	405021	USD
CY2013	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	USD
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2012	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	385905	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2010Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2012	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4152343	USD
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax	-6014981	USD
CY2013	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax	0	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	214871	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	598729	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4314228	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1614858	USD
CY2012	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	5394263	USD
CY2013	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	0	USD
CY2013	us-gaap	Payments For Repurchase Of Redeemable Preferred Stock PaymentsForRepurchaseOfRedeemablePreferredStock	200000	USD
CY2012	us-gaap	Payments Of Dividends PaymentsOfDividends	327748	USD
CY2013	us-gaap	Payments Of Dividends PaymentsOfDividends	0	USD
CY2013	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	3100000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2691471	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	531315	USD
CY2012	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	528023	USD
CY2013	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2012	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	528023	USD
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2351558	shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	803135	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1561933	USD
CY2013	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2012	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	12280000	USD
CY2012	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	16428827	USD
CY2013	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	58736165	USD
CY2012	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	666501	USD
CY2013	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1041347	USD
CY2012	us-gaap	Proceeds From Repurchase Of Redeemable Preferred Stock ProceedsFromRepurchaseOfRedeemablePreferredStock	2500000	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	150658	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3028241	USD
CY2012	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6604418	USD
CY2013	us-gaap	Profit Loss ProfitLoss	-39485334	USD
CY2012	us-gaap	Profit Loss ProfitLoss	-66369311	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15867000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13175600	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11153143	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12844216	USD
CY2013Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	2743700	USD
CY2012Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1800600	USD
CY2013	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	503172	USD
CY2012	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	440477	USD
CY2012	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	196585	USD
CY2013	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	201754	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16917396	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10451070	USD
CY2012	us-gaap	Restatement Of Prior Year Income Net Of Tax RestatementOfPriorYearIncomeNetOfTax	321600	USD
CY2013	us-gaap	Restatement Of Prior Year Income Net Of Tax RestatementOfPriorYearIncomeNetOfTax	-91400	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-197392361	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-236373605	USD
CY2012	us-gaap	Revenues Revenues	14329889	USD
CY2013	us-gaap	Revenues Revenues	14668455	USD
CY2012	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	1117901	USD
CY2013	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	0	USD
CY2013Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.60
CY2010Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.945
CY2013Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	213112	USD
CY2012Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	3438475	USD
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22315346	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21612793	USD
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P3Y7M6D
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4780658	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1658100	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1604000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1283300	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1658100	USD
CY2012	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	229553	shares
CY2013	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	514700	shares
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16428827	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	58736166	USD
CY2012	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1325100	USD
CY2013	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	3360000	USD
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6712536	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6838559	USD
CY2012	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1117901	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	33177129	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	62542475	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	62026435	USD
CY2012Q4	us-gaap	Temporary Equity Liquidation Preference Per Share TemporaryEquityLiquidationPreferencePerShare	0.00
CY2012Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2013Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	32820159	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	80132518	USD
CY2013Q4	us-gaap	Temporary Equity Liquidation Preference Per Share TemporaryEquityLiquidationPreferencePerShare	0.00
CY2013Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2012Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2012Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	6662748	shares
CY2013Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	3135411	shares
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	705742	USD
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	665600	USD
CY2012	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	373307	USD
CY2013	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	77981	USD
CY2013Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	59726600	USD
CY2012Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	39144700	USD
CY2012Q4	nbs	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	1300000	USD
CY2013Q4	nbs	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	1811000	USD
CY2013Q4	nbs	Aggregate Intrinsic Value Warrantsvested AggregateIntrinsicValueWarrantsvested	1811000	USD
CY2013Q4	nbs	Aggregate Intrinsic Value Warrantsvestedandexpectedtovest AggregateIntrinsicValueWarrantsvestedandexpectedtovest	1811000	USD
CY2012Q3	nbs	Base Monthly Rent Expense Of Executive Offices BaseMonthlyRentExpenseOfExecutiveOffices	27000	USD
CY2012Q3	nbs	Base Monthly Rent Expense Of Subleases BaseMonthlyRentExpenseOfSubleases	7500	USD
CY2012	nbs	Clinical Services Reimbursement ClinicalServicesReimbursement	3500000	USD
CY2013	nbs	Clinical Services Reimbursement ClinicalServicesReimbursement	2100000	USD
CY2013	nbs	Common Stock Issued In Payment Of Dividends For Convertible Redeemable Series E7 Preferred Stock CommonStockIssuedInPaymentOfDividendsForConvertibleRedeemableSeriesE7PreferredStock	3400000	USD
CY2012Q4	nbs	Common Stock Warrants Shares CommonStockWarrantsShares	5528761	shares
CY2013Q4	nbs	Deferred Tax Liabilities Accumulated Depreciation DeferredTaxLiabilitiesAccumulatedDepreciation	64800	USD
CY2012Q4	nbs	Deferred Tax Liabilities Accumulated Depreciation DeferredTaxLiabilitiesAccumulatedDepreciation	0	USD
CY2013	nbs	Dividend On Preferred Stock Shares Of Common Stock Issuable DividendOnPreferredStockSharesOfCommonStockIssuable	0	USD
CY2012	nbs	Dividend On Preferred Stock Shares Of Common Stock Issuable DividendOnPreferredStockSharesOfCommonStockIssuable	175700	USD
CY2013	nbs	Income Tax Reconciliation Undistributed Foreign Earnings IncomeTaxReconciliationUndistributedForeignEarnings	0	USD
CY2012	nbs	Income Tax Reconciliation Undistributed Foreign Earnings IncomeTaxReconciliationUndistributedForeignEarnings	-1810300	USD
CY2012	nbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	1677551	USD
CY2013	nbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	2916739	USD
CY2012	nbs	Issuance Of Common Stock In Connection With Preferred Stock Settlement Value IssuanceOfCommonStockInConnectionWithPreferredStockSettlementValue	674194	USD
CY2013	nbs	Issuance Of Common Stock In Exchange For Convertible Preferred Stock IssuanceOfCommonStockInExchangeForConvertiblePreferredStock	0	USD
CY2012	nbs	Issuance Of Common Stock In Exchange For Convertible Preferred Stock IssuanceOfCommonStockInExchangeForConvertiblePreferredStock	1026600	USD
CY2012	nbs	Other Comprehensive Income Foreign Currency Translation Elimination On Sale Of Segment OtherComprehensiveIncomeForeignCurrencyTranslationEliminationOnSaleOfSegment	-10402352	USD
CY2013	nbs	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	234225	USD
CY2012	nbs	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Elimination On Exit Of Segment OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationEliminationOnExitOfSegment	-169993	USD
CY2013	nbs	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Elimination On Exit Of Segment OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationEliminationOnExitOfSegment	0	USD
CY2013	nbs	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Elimination On Sale Of Segment OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationEliminationOnSaleOfSegment	0	USD
CY2012	nbs	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Elimination On Sale Of Segment OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationEliminationOnSaleOfSegment	-4387371	USD
CY2012	nbs	Payment For Warrant Inducement PaymentForWarrantInducement	228676	USD
CY2013	nbs	Payment For Warrant Inducement PaymentForWarrantInducement	62014	USD
CY2013Q2	nbs	Percentofoutstandingcommonstock Percentofoutstandingcommonstock	0.1
CY2012	nbs	Permanent Non Deductible Expenses For Us Taxes PermanentNonDeductibleExpensesForUSTaxes	2781400	USD
CY2013	nbs	Permanent Non Deductible Expenses For Us Taxes PermanentNonDeductibleExpensesForUSTaxes	1798200	USD
CY2010Q4	nbs	Preferred Offering Units PreferredOfferingUnits	10582011	shares
CY2012Q4	nbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2013Q4	nbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2012	nbs	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	-511755	USD
CY2013	nbs	Revene Recognition Period For Cryoperservation Process ReveneRecognitionPeriodForCryoperservationProcess	PT24H
CY2013Q4	nbs	Sharesvestedandexpectedtovest Sharesvestedandexpectedtovest	4884957	shares
CY2012	nbs	Stock Issued During Period Shares Warrant Inducements StockIssuedDuringPeriodSharesWarrantInducements	41969	shares
CY2013	nbs	Stock Issued During Period Shares Warrant Inducements StockIssuedDuringPeriodSharesWarrantInducements	40407	shares
CY2012	nbs	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	6604419	USD
CY2013	nbs	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	3028241	USD
CY2012	nbs	Stock Issued During Period Value Warrant Inducements StockIssuedDuringPeriodValueWarrantInducements	228676	USD
CY2013	nbs	Stock Issued During Period Value Warrant Inducements StockIssuedDuringPeriodValueWarrantInducements	62014	USD
CY2013Q4	nbs	Stock Option Exercise StockOptionExercise	30000	shares
CY2013	nbs	Warrant Inducements WarrantInducements	0	USD
CY2012	nbs	Warrant Inducements WarrantInducements	-1012819	USD
CY2013	nbs	Warrants Canceled WarrantsCanceled	136079	shares
CY2013	nbs	Warrants Exercised WarrantsExercised	563166	shares
CY2013	nbs	Warrants Expired WarrantsExpired	17500	shares
CY2013	nbs	Warrants Granted WarrantsGranted	86250	shares
CY2013	nbs	Warrants Issued During Period Value WarrantsIssuedDuringPeriodValue	149900	USD
CY2012	nbs	Warrants Issued During Period Value WarrantsIssuedDuringPeriodValue	172200	USD
CY2013	nbs	Weighted Average Estimated Fair Value Of Restricted Stock WeightedAverageEstimatedFairValueOfRestrictedStock	6.53
CY2012Q1	nbs	Weighted Average Estimated Fair Value Of Restricted Stock WeightedAverageEstimatedFairValueOfRestrictedStock	5.77
CY2013	nbs	Weighted Average Exercise Price Warrants Canceled WeightedAverageExercisePriceWarrantsCanceled	20.15
CY2013Q4	nbs	Weighted Average Exercise Price Warrants Exercisable WeightedAverageExercisePriceWarrantsExercisable	15.41
CY2013	nbs	Weighted Average Exercise Price Warrants Exercised WeightedAverageExercisePriceWarrantsExercised	5.38
CY2013	nbs	Weighted Average Exercise Price Warrants Expired WeightedAverageExercisePriceWarrantsExpired	14.20
CY2013	nbs	Weighted Average Exercise Price Warrants Granted WeightedAverageExercisePriceWarrantsGranted	6.66
CY2012Q4	nbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	15.65
CY2013Q4	nbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	16.50
CY2013Q4	nbs	Weighted Average Exercise Price Warrantsvestedexpectedtovest WeightedAverageExercisePriceWarrantsvestedexpectedtovest	16.35
CY2013	nbs	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P2Y7M17D
CY2013	nbs	Weighted Average Remaining Contractual Termwarrantsvested WeightedAverageRemainingContractualTermwarrantsvested	P2Y7M2D
CY2013	nbs	Weightedaveragenumberbasicdilutedsharesoutstanding Weightedaveragenumberbasicdilutedsharesoutstanding	20495771	shares
CY2012	nbs	Weightedaveragenumberbasicdilutedsharesoutstanding Weightedaveragenumberbasicdilutedsharesoutstanding	13841997	shares
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0000320017
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28582625	shares
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q2	dei	Entity Public Float EntityPublicFloat	92272275	USD
CY2013	dei	Entity Registrant Name EntityRegistrantName	NeoStem, Inc.
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No

Files In Submission

Name	View Source	Status
0000320017-14-000007-index-headers.html	Edgar Link	pending
0000320017-14-000007-index.html	Edgar Link	pending
0000320017-14-000007.txt	Edgar Link	pending
0000320017-14-000007-xbrl.zip	Edgar Link	pending
clinicalmilestonesv173finaln.jpg	Edgar Link	pending
exh1049rs.htm	Edgar Link	pending
exh1057.htm	Edgar Link	pending
exh211.htm	Edgar Link	pending
exh231.htm	Edgar Link	pending
exhibit1010spa.htm	Edgar Link	pending
exhibit418rr.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
finalfinalbusinessmodel.jpg	Edgar Link	pending
finalfinaltreg.jpg	Edgar Link	pending
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
nbs-10kx20131231.htm	Edgar Link	pending
nbs-20131231.xml	Edgar Link	completed
nbs-20131231.xsd	Edgar Link	pending
nbs-20131231_cal.xml	Edgar Link	unprocessable
nbs-20131231_def.xml	Edgar Link	unprocessable
nbs-20131231_lab.xml	Edgar Link	unprocessable
nbs-20131231_pre.xml	Edgar Link	unprocessable
nbs-ex311_20121231xq4.htm	Edgar Link	pending
nbs-ex312_20121231xq4.htm	Edgar Link	pending
nbs-ex321_20121231xq4.htm	Edgar Link	pending
nbs-ex322_20121231xq4.htm	Edgar Link	pending
pctfinalfullspectrumofservic.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

2014 Q1 Form 10-K Financial Statement

#000032001714000007 Filed on March 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA LISATA THERAPEUTICS, INC. Stock $lsta

2014 Q1 Form 10-K Financial Statement

#000032001714000007 Filed on March 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta